Feedback
Settings

Settings

Goto Application

310,969 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 31,097
1.WO/2024/084932CARRIER PEPTIDE FRAGMENT AND USE THEREOF
WO - 25.04.2024
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
 Appl.No PCT/JP2023/035845 Applicant TOAGOSEI CO.,LTD. Inventor BAILEYKOBAYASHI, Nahoko
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comprises the amino acid sequence KFRAQRRW (SEQ ID NO: 1).
2.WO/2024/084497METHOD FOR MANUFACTURING RECOMBINANT TRANSFERRIN BINDING PROTEINS AND VACCINE COMPOSITIONS COMRPISING SAME
WO - 25.04.2024
Int.Class C07K 14/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
22from Neisseriaceae (F), e.g. Acinetobacter
 Appl.No PCT/IN2023/050922 Applicant SERUM INSTITUTE OF INDIA PVT. LTD., Inventor KARALE, Abhijeet Jagannath
The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transferrin binding protein (rTbp-B) along with high recovery, low impurity/ aggregate content, and at the same time retains the integrity of the protein. The method uses a single chromatographic step and does not require tagging of proteins as compared to multiple chromatographic steps used previously and still manages to provide r-Tbp-B with at least 95 % purity.
3.WO/2024/085697STABLE ANTIBODY COMPOSITION
WO - 25.04.2024
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/KR2023/016295 Applicant CHONG KUN DANG PHARMACEUTICAL CORP. Inventor LEE, Yoon Seok
The present disclosure relates to an aqueous pharmaceutical composition, a method of preparing the same, and use thereof, the aqueous pharmaceutical composition including: risankizumab or an antigen-binding fragment thereof; and a stabilizer, wherein the aqueous pharmaceutical composition does not include a polyol.
4.WO/2024/082262SPLICING SYSTEM FOR CONTROLLING VIRUS REPLICATION IN RESPONSE TO HYPOXIC ENVIRONMENT, AND USE THEREOF
WO - 25.04.2024
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2022/126655 Applicant SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD. Inventor XU, Jianqing
Provided are a splicing system for controlling virus replication in response to a hypoxic environment, and a use thereof. The system comprises, mutually separated or fused to one another, a gene encoding an hypoxia sensing unit and a gene encoding a virus replication control unit, wherein the gene encoding the hypoxia sensing unit comprises an N-terminal splicing domain element and an oxygen-sensitive protein element which are connected to one another, and the gene encoding the virus replication control unit comprises a C-terminal splicing domain element and a virus replication key factor element which are connected via a degradation subelement. The splicing system can respond to a hypoxia condition signal, thereby achieving splicing of a virus replication key factor in response to the hypoxic environment, and exhibiting characteristics of low expression of the virus replication key factor in a normal tissue environment, and enrichment in a tumor microenvironment.
5.WO/2024/082067MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARBECOVIRUSES
WO - 25.04.2024
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CA2023/051399 Applicant THE HOSPITAL FOR SICK CHILDREN Inventor JULIEN, Jean-Philippe
Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Also described are methods for treating and/or preventing sarbecovirus infection and/or a sarbecovirus-associated condition.
6.WO/2024/083162ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOF
WO - 25.04.2024
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2023/125261 Applicant MULTITUDE THERAPEUTICS INC. Inventor MENG, Xun
Provided are the antibodies specific targeting CD142, antibody-drug conjugates, preparations and uses thereof. The antibody or antigen-binding fragment thereof binding to CD142 is covalently linked to a cytotoxic payload through a linker. The antibody or antigen-binding fragment thereof binding to CD142 and the antibody-drug conjugate exhibit cytotoxic effects on tumor cells.
7.WO/2024/083867BIOMARKER
WO - 25.04.2024
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/EP2023/078887 Applicant ULTIMOVACS ASA Inventor ELLINGSEN, Espen Basmo
A method for identifying a subject to whom a combination therapy is to be administered, wherein the subject is a cancer patient. The combination therapy comprises administration of: (I) a PD-1/PD-L1 immune checkpoint inhibitor and/or a CTLA-4 immune checkpoint inhibitor, with (II) a polypeptide comprising a region of at least 12 amino acids of a tumor-associated antigen. The method comprises: (a) evaluating a level of one or more of (i) to (iv) in a biological sample obtained from a cancer patient: (i) tumor mutational burden; (ii) PD-L1 expression; (iii) a tumor infiltrating lymphocyte; and/or (iv) neoantigens, wherein the level of one or more of (i) to (iv) is determined to be low; and (b) identifying the cancer patient who provided the biological sample as a subject to whom the combination therapy is to be administered.
8.WO/2024/083912GLYCOSYLATED YGHJ POLYPEPTIDES FROM UROPATHOGENIC E. COLI
WO - 25.04.2024
Int.Class C07K 14/245
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
24from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
245Escherichia (G)
 Appl.No PCT/EP2023/078991 Applicant GLYPROVAC APS Inventor BOYSEN, Anders
The present invention relates to YGHJ polypeptides with novel glycosylation patterns. The glycosylated polypeptides are expressed in an avirulent genetically altered strain of the natural pathogenic bacteria, which gives rise to glycosylated YGHJ polypeptides which resembles the wildtype polypeptide to a higher degree than polypeptides expressed in E. coli production strains. The invention also relates to uses of such polypeptides and production strains.
9.WO/2024/086747RECOMBINANT AAVS WITH IMPROVED TROPISM AND SPECIFICITY
WO - 25.04.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/US2023/077340 Applicant AFFINIA THERAPEUTICS INC. Inventor ALBRIGHT, Charles, Francis
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistribution in vivo or in vitro. The rAAV of the present disclosure can be used for gene therapies targeted at a specific tissue.
10.WO/2024/086777COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY VIRUSES AND BACTERIA
WO - 25.04.2024
Int.Class C07K 5/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
 Appl.No PCT/US2023/077392 Applicant THE TRUSTEES OF INDIANA UNIVERSITY Inventor SCOTT, William Leonard
Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
# -